Bringing Cerebral Palsy (CP) Into the Genomics Era

Tuesday, January 17

12:30pm

Hybrid: Rosedale Room and Zoom

For Researchers



Speaker:

Siddharth Srivastava, M.D. Assistant Professor of Neurology Boston Children's Hospital, Harvard Medical School Boston, MA

Host: Rajiv R. Ratan, M.D., Ph.D.

For more information contact **Darlene White**daw9085@med.cornell.edu

Burke Neurological Institute

Academic Affiliate of Weill Cornell Medicine 785 Mamaroneck Avenue, White Plains, NY 10605 burke.weill.cornell.edu/events

Abstract

As the most common childhood-onset motor disability, cerebral palsy (CP) affects 764,000 individuals in the United States alone and accounts for lifetime healthcare expenses of \$1.4 million per person. In approximately 20% of cases (or 150,000 individuals), the cause is unknown, raising concern for a genetic disorder, including treatable conditions where a molecular diagnosis may positively alter the trajectory of a child's development. Our research aims to (1) determine the genetic landscape of CP, including potentially treatable conditions (2) develop rules to predict which individuals with CP are likely to have a genetic disorder and (3) contribute to an emerging scientific understanding of the pathophysiology of CP that will impact a large patient population.


- Spastic quadriplegic CP
- Profound ID
- Epilepsy
- Microcephaly
- Short stature
- Failure to thrive
- Cerebral atrophy
- Leukoencephalopathy
- Perinatal adversity


LYARCA C.938A>T


WARS2 c.938A>T p.(K313M)

WARS2 c.298_300delCTT p.(L100del)

Compound heterozygous







3. Srivastava S, Jo B, Zhang B, Frazier T, Gallagher A, Peck F, Levin A, Mondal S, Li Z, Filip-Dhima R, Geisel G, Dies K, Diplock A, Eng C, Hanna R, Sahin M, Hardan A. A randomized controlled trial of Everolimus for neurocognitive symptoms in PTEN hamartoma tumor syndrome. Hum Mol Genet . 2022 May 20. PubMed PMID: 35594551.



